<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333644</url>
  </required_header>
  <id_info>
    <org_study_id>HIV FMD AGING</org_study_id>
    <nct_id>NCT01333644</nct_id>
  </id_info>
  <brief_title>The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk</brief_title>
  <official_title>The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the central hypothesis of the investigators study that HIV disease is a&#xD;
      pro-inflammatory condition, and that years of inflammation result in premature &quot;aging' of the&#xD;
      immune system (&quot;immunosenescence&quot;). Just as these changes are thought be causally associated&#xD;
      with heart disease in the very old,the investigators postulate that these changes will be&#xD;
      associated with early heart disease in the untreated and perhaps treated HIV disease. To&#xD;
      address this hypothesis, the investigators will measure immunosenescence in a large cohort of&#xD;
      patients who span the entire disease process.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>brachial artery flow-mediated dilatation</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>HIV Infection</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>HIV-Infection</arm_group_label>
    <description>Treated HIV-infected individuals with an undetectable HIV RNA level (&lt; 75 copies RNA/mL, untreated HIV-infected individuals, and HIV-uninfected individuals.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, PBMCs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Treated and untreated HIV-infected individuals and HIV-uninfected individuals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV controllers: positive for HIV by standard antibody serological determinations with&#xD;
             undetectable HIV RNA level (&lt; 75 copies RNA/mL) in absence of therapy&#xD;
&#xD;
          -  HIV non-controllers: detectable HIV RNA levels in absence of therapy&#xD;
&#xD;
          -  Highly active anti-retroviral therapy responders (HAART responders): on combination&#xD;
             antiretroviral therapy with undetectable HIV RNA levels.&#xD;
&#xD;
          -  HIV-seronegative participants will also be studied.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treated individuals that changed antiretroviral regimen within 12 weeks prior to study&#xD;
             enrollment.&#xD;
&#xD;
          -  Individuals who have started or stopped antihypertensive medication or lipid lowering&#xD;
             medication or changed doses of these drugs within 12 weeks of the study will be&#xD;
             excluded.&#xD;
&#xD;
          -  As nitroglycerin is administered to assess endothelium-independent vasodilation, we&#xD;
             also plan to exclude patients who have taken sildenafil, vardenafil, or tadalafil&#xD;
             within 72 hours of the endothelial function study, or who are hypotensive (systolic BP&#xD;
             &lt;100).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priscilla Hsue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2011</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Infection</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Antiretroviral medication</keyword>
  <keyword>Treatment naive</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

